Clinical review report. Ozenoxacin 1% cream (Ozanex) (Ferrer internacional, S.A.) : indication : the topical treatment of impetigo in patients aged two months and older.

Clinical review report. indication : the topical treatment of impetigo in patients aged two months and older. Ozenoxacin 1% cream (Ozanex) (Ferrer internacional, S.A.) :

Show other versions (2)

The objective of this report is to perform a systematic review of the beneficial and harmful effects of ozenoxacin 1% cream for the topical treatment of impetigo in patients aged two months and older.

Saved in:

Bibliographic Details
Online Access:	Full text
Format:	Electronic eBook
Language:	English
Published:	Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018
Series:	Common drug review clinical review report.
Subjects:	Impetigo > drug therapy. Infant. Child. Aminopyridines > therapeutic use. Quinolones > therapeutic use. Treatment Outcome. Children. Family members. Canada. Systematic Review. Tables.

Description
Summary:	The objective of this report is to perform a systematic review of the beneficial and harmful effects of ozenoxacin 1% cream for the topical treatment of impetigo in patients aged two months and older.
Item Description:	"Version: Final."
Physical Description:	1 online resource (1 PDF file (86 pages)).
Bibliography:	Includes bibliographical references.
Source of Description, Etc. Note:	Description based on online resource; title from PDF title page (viewed June 17, 2019).
Funding Information Note:	Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.